Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients

High-dose therapy followed by Autologous Stem Cell Transplantation (ASCT) is the gold standard treatment in newly diagnosed Multiple Myeloma (MM) patients who result eligible for this procedure [1]...

[1]  T. Willis,et al.  Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. , 2018, Blood.

[2]  M. Sancar,et al.  Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[3]  B. Pégourié,et al.  Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02) , 2017 .

[4]  H. Goldschmidt,et al.  From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives , 2017, Haematologica.

[5]  A. Órfão,et al.  Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Siegel,et al.  A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  P. Neri,et al.  Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant , 2016, Leukemia & lymphoma.

[8]  M. Dimopoulos,et al.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.

[9]  D. Esseltine,et al.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.

[10]  H. Prince,et al.  Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma , 2011, Bone Marrow Transplantation.

[11]  Mourad Tighiouart,et al.  A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study , 2010, Clinical Cancer Research.

[12]  B. Pégourié,et al.  Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). , 2010, Blood.

[13]  H. Avet-Loiseau,et al.  The role of complete response in multiple myeloma. , 2009, Blood.

[14]  U. Steidl,et al.  High‐dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment‐related mortality in patients with multiple myeloma: results of a randomised study , 2005, British journal of haematology.

[15]  K. Anderson,et al.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.